Invest1 publisher2 min readPublished
Japan's obesity society warns cosmetic Mounjaro users off crash dieting on the drug
Japan's obesity society warned cosmetic GLP-1 users of side-effect risks, as 35 of about 950 Mounjaro side-effect reports involved dieting or cosmetic use. The health ministry separately said the drugs should not be used casually as weight-loss pills.
The Investor · Invest desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- The society said cutting food sharply while on the drugs can build up ketones, causing vomiting, abdominal pain and severe fatigue, and in worse cases ketoacidosis that may need emergency care.
- Mounjaro, a tirzepatide injection, is approved in Japan for type 2 diabetes, while the obesity version, Zepbound, carries dosing criteria tied to degree of obesity and health problems.
- Some Japanese medical institutions prescribe these prescription-only drugs for cosmetic or weight-loss use through "free treatment", care that health insurance does not cover.
- A perception that Mounjaro is cheap in Japan has drawn buyers from abroad, and South Koreans coined "sushi-zaro" for getting it prescribed or bought there.
- The health ministry said person-to-person sales of the drugs on social media or secondhand sites are illegal and may involve counterfeit or degraded products.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- decision Each free-treatment clinic now decides whether to keep prescribing tirzepatide for appearance with the specialist obesity society's warning on the public record.
- exposure Buyers who skip clinics to chase Japan's lower price take on counterfeit and quality risk, with no doctor overseeing the dose or the diet that the society says causes harm.
- constraint With off-label cases at about 3.7% of filings and no prescription figures published, the warning cannot yet be tied to any change in Mounjaro or Wegovy volumes in Asia.
Thirty-five off-label reports out of about 950 is 3.7% [1]. That is a small share for a warning worded this strongly. Each report is a harm that someone filed with the Pharmaceuticals and Medical Devices Agency [2]. Cosmetic users who had no problem, or who had one and filed nothing, are not in the count. The share therefore cannot be read as an injury rate among people taking Mounjaro for appearance.
The society's concern is the population itself. People without obesity or diabetes who take the drugs for appearance may get side effects that existing clinical trials did not sufficiently verify, it said in a statement reported by NHK and Kyodo News [1][5]. Such users meet the criteria for neither of tirzepatide's Japanese labels [6].
On dieting it was blunt. Using the drugs while severely restricting food intake "must absolutely be avoided," the society said, according to Kyodo [4]. GLP-1 drugs also carry known risks of pancreatitis and intestinal obstruction [12].
The warnings can play out in a few ways. They can stay as advice, with the uninsured free-treatment clinics [7] prescribing as before and demand set by how patients judge the risk. The health ministry has already said that the safety and effectiveness of cosmetic or dieting use have not been established in some cases [13]. It could turn that position into a rule on uninsured prescribing. Or the price gap that brings Korean buyers to Japan [11] keeps pulling demand whatever the doctors say, because a safety notice does not change what a dose costs.
I think the first outcome is the likeliest, because the statements shift risk without shifting money. Japan's relief system for drug-injury damage pays, in principle, when serious harm follows use for the approved purpose at the approved dose [10]. The ministry said people harmed after cosmetic or dieting use are unlikely to be compensated [10]. A cosmetic patient already pays the clinic outside insurance [7]. Under the relief rule the same patient carries the cost of a serious injury, and the clinic keeps its fee. The counter-case is that a formal statement from the specialist society carries enough weight with doctors that clinics drop these prescriptions without being told to. If free-treatment clinics stop offering tirzepatide for weight loss before any new rule appears, that case is right and mine is wrong.
What to watch
- Whether the health ministry moves from warnings to restrictions on prescribing GLP-1 drugs through uninsured free treatment.
- The next PMDA tally of off-label Mounjaro reports, measured against the current 35 of about 950.
- Whether South Korean demand for Japan-sourced Mounjaro falls after the ministry's statement that resale through social media is illegal.